Compare CQP & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CQP | GEHC |
|---|---|---|
| Founded | 2003 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Computer Software: Prepackaged Software |
| Sector | Utilities | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3B | 27.9B |
| IPO Year | 2006 | 2022 |
| Metric | CQP | GEHC |
|---|---|---|
| Price | $68.43 | $72.59 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 7 | 13 |
| Target Price | $60.43 | ★ $88.38 |
| AVG Volume (30 Days) | 107.2K | ★ 5.1M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 5.05% | 0.24% |
| EPS Growth | N/A | ★ 4.84 |
| EPS | 0.07 | ★ 0.85 |
| Revenue | $10,758,000,000.00 | ★ $20,625,000,000.00 |
| Revenue This Year | $6.35 | $7.12 |
| Revenue Next Year | $1.27 | $4.45 |
| P/E Ratio | $983.86 | ★ $85.35 |
| Revenue Growth | ★ 23.60 | 4.84 |
| 52 Week Low | $49.53 | $58.75 |
| 52 Week High | $70.64 | $89.77 |
| Indicator | CQP | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 59.94 | 65.79 |
| Support Level | $61.69 | $69.17 |
| Resistance Level | $70.64 | $72.77 |
| Average True Range (ATR) | 2.20 | 2.10 |
| MACD | 0.22 | 0.65 |
| Stochastic Oscillator | 96.30 | 93.46 |
Cheniere Energy Partners is a liquified natural gas producer operating one facility in Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. The profit generated through those activities is split with parent and operator Cheniere Energy.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).